RecruitingNCT05862259

A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies

A Multicenter, Multiomics, Non-interventional, Real-world Study of the Efficacy and Safety of Immune Checkpoint Inhibitors as First-line Therapy for Advanced Malignancies

Sponsor

Xinqiao Hospital of Chongqing

Enrollment

120 participants

Start Date

Aug 10, 2023

Study Type

OBSERVATIONAL

Conditions

Immunotherapy Artificial Intelligence Malignant Tumor

Summary

In this study, we collected the data of immunohistochemistry, gene detection, image, OS, PFS, Orr, and so on. Secondly, the database of immunotherapy for malignant tumor was established, and the predictive model was constructed to verify and establish the rationality and validity of the biomarkers and predictive system of immunotherapy

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria6

Informed consent has been signed and, in the judgment of the investigator, the patient is able to comply with the study protocol and sign a written informed consent.
the advanced malignant tumors (solid tumors of the non-small-cell lung carcinoma, stomach, breast, urinary system, etc.) were diagnosed by histopathology.
the stage IV according to the eighth edition of IASLC.
PS 0-2, the expected survival > 3 months.
the age of 18-75 years.
no contraindication to treatment with immune checkpoint inhibitors.

Exclusion Criteria4

the patients' compliance was poor, which violated the rules of the trial;
the patients with severe dysfunction of vital organs (heart, liver and kidney) ;
the patients with other malignant tumors;
the researchers considered that the patients should not participate in other conditions of the trial.

Interested in this trial?

Get notified about updates and connect with the research team.